Abiraterone With Different Steroid Regimens for Side Effect Related to Mineralcorticoid Excess Prevention in Prostate Cancer Prior to Chemotherapy

This study is currently recruiting participants. (see Contacts and Locations)
Verified March 2015 by Janssen Pharmaceutica N.V., Belgium
Sponsor:
Information provided by (Responsible Party):
Janssen Pharmaceutica N.V., Belgium
ClinicalTrials.gov Identifier:
NCT01867710
First received: May 30, 2013
Last updated: March 3, 2015
Last verified: March 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: July 2018
  Estimated Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)